Serina Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Serina Therapeutics, Inc. (SER) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$8.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-13
- Serina Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$8.93M.
- Serina Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$6.93M.
- Serina Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$3.37M.
- Serina Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$4.69M, a 432.34% decline year-over-year.
- Serina Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$19.44M.
- Serina Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$11.14M, a 308.17% decline from fiscal 2023.
- Serina Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was $5.35M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.93M 10-Q · filed 2026-08-13 | -$15.87M 10-Q · filed 2026-08-13 | -$19.24M derived: sum of 3 quarters · filed 2026-08-13 | -$23.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$6.93M 10-Q · filed 2026-05-14 | -$10.31M derived: sum of 2 quarters · filed 2026-05-14 | -$14.99M derived: sum of 3 quarters · filed 2026-05-14 | -$21.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$8.06M derived: sum of 2 quarters · filed 2026-03-25 | -$14.62M derived: sum of 3 quarters · filed 2026-08-13 | -$19.44M 10-K · filed 2026-03-25 |
| 2025-09-30 | -$4.69M 10-Q · filed 2025-11-13 | -$11.25M derived: sum of 2 quarters · filed 2026-08-13 | -$16.06M 10-Q · filed 2025-11-13 | -$18.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$6.57M 10-Q · filed 2026-08-13 | -$11.38M 10-Q · filed 2026-08-13 | -$14.12M derived: sum of 3 quarters · filed 2026-08-13 | -$12.71M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$4.81M 10-Q · filed 2026-05-14 | -$7.55M derived: sum of 2 quarters · filed 2026-05-14 | -$6.14M derived: sum of 3 quarters · filed 2026-05-14 | -$939.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$1.33M derived: sum of 2 quarters · filed 2026-03-25 | $3.87M derived: sum of 3 quarters · filed 2026-03-25 | -$11.14M 10-K · filed 2026-03-25 |
| 2024-09-30 | $1.41M 10-Q · filed 2025-11-13 | $6.61M derived: sum of 2 quarters · filed 2025-11-13 | -$8.40M 10-Q · filed 2025-11-13 | -$1.77M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $5.20M 10-Q · filed 2025-08-11 | -$9.81M 10-Q · filed 2025-08-11 | -$3.18M derived: sum of 3 quarters · filed 2025-08-11 | -$1.42M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$9.44M 10-Q · filed 2024-05-14 | -$8.39M derived: sum of 2 quarters · filed 2025-03-24 | -$6.63M derived: sum of 3 quarters · filed 2025-03-24 | -$5.80M derived: sum of 4 quarters · filed 2025-03-24 |
| 2023-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $2.81M derived: sum of 2 quarters · filed 2025-03-24 | $3.64M derived: sum of 3 quarters · filed 2025-03-24 | $5.35M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.76M 10-Q · filed 2024-11-12 | $2.59M derived: sum of 2 quarters · filed 2024-11-12 | $4.30M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $830.00K 10-Q · filed 2024-08-09 | $2.54M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $1.74M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |